Unknown

Dataset Information

0

Strategies targeting angiogenesis in advanced non-small cell lung cancer.


ABSTRACT: Tumor angiogenesis is a frequent event in the development and progression of non-small cell lung cancer (NSCLC) and has been identified as a promising therapeutic target. The vascular endothelial growth factor (VEGF) family and other angiogenic factors, including fibroblast growth factor and platelet-derived growth factor, promote the growth of newly formed vessels from preexisting vessels and change the tumor microenvironment. To date, two antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab, which target VEGF-A and its receptor VEGF receptor-2, respectively, have been approved for the treatment of locally advanced or metastatic NSCLC when added to first-line standard chemotherapy. Numerous oral multitargeting angiogenic small molecule tyrosine kinase inhibitors (TKIs) have been widely evaluated in advanced NSCLC, but only nintedanib in combination with platinum-based doublet chemotherapy has demonstrated a survival benefit in the second-line setting. Additionally, small-molecule TKIs remain the standard of care for patients with mutated EGFR, ALK or ROS1. Moreover, immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) are changing the current strategy in the treatment of advanced NSCLC without driver gene mutations. The potential synergistic activity of antiangiogenic agents and TKIs or immunotherapy is an interesting topic of research. This review will summarize the novel antiangiogenic agents, antiangiogenic monotherapy, as well as potential combination therapeutic strategies for the clinical management of advanced NSCLC.

SUBMITTER: Wang J 

PROVIDER: S-EPMC5581155 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Strategies targeting angiogenesis in advanced non-small cell lung cancer.

Wang Jun J   Chen Jianpeng J   Guo Yan Y   Wang Baocheng B   Chu Huili H  

Oncotarget 20170517 32


Tumor angiogenesis is a frequent event in the development and progression of non-small cell lung cancer (NSCLC) and has been identified as a promising therapeutic target. The vascular endothelial growth factor (VEGF) family and other angiogenic factors, including fibroblast growth factor and platelet-derived growth factor, promote the growth of newly formed vessels from preexisting vessels and change the tumor microenvironment. To date, two antiangiogenic monoclonal antibodies, bevacizumab and r  ...[more]

Similar Datasets

| S-EPMC6628716 | biostudies-literature
| S-EPMC4014113 | biostudies-literature
| S-EPMC5009078 | biostudies-literature
| S-EPMC5642641 | biostudies-literature
| S-EPMC4830020 | biostudies-literature
| S-EPMC5627646 | biostudies-literature
| S-EPMC5952024 | biostudies-literature
| S-EPMC4697681 | biostudies-literature
| S-EPMC4325981 | biostudies-other
| S-EPMC8784727 | biostudies-literature